Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity

Note: Funding Information: This reported studies were embedded in the Siallergen consortium, which was supported by Health Holland. The work of the authors has further been supported by Angany Inc. (Quebec, Canada), the Austrian Science Funds (FWF Project P32189), the University of Salzburg priority program “Allergy-Cancer-BioNano Research Centre”, and a grant from the National Institute of Allergy and Infectious Diseases of the National Institute of Health, Bethesda, MD, USA (RO1AI165866 (SCD)). Funding Information: This reported studies were embedded in the Siallergen consortium, which was supported by Health Holland. The work of the authors has further been supported by Angany Inc. (Quebec, Canada), the Austrian Science Funds (FWF Project P32189), the University of Salzburg priority program “Allergy‐Cancer‐BioNano Research Centre”, and a grant from the National Institute of Allergy and Infectious Diseases of the National Institute of Health, Bethesda, MD, USA (RO1AI165866 (SCD)). Funding Information: Charlotte Castenmiller, Lorenz Aglas, and Maria Stigler received contract research funding and study material from Angany Inc. Louis‐P Vézina is a cofounder board member, and CEO of Angany Inc. Réjean Desgagnés, Caroline Martel, Lydia Auger, Joanie Roberge, Bertrand Morel, Virginie Stordeur, Lucie Mirande, Guy Tropper, and Véronique Gomord are employees of Angany Inc. Ronald van Ree received contract research funding and research material form Angany Inc. and besides received consulting fees and/or speaker's fees from Angany Inc. HAL Allergy BV, Citeq BV, ThermoFisher Scientific, Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes, and has stock options from Angany.